Shares of Leap Therapeutics Inc (NASDAQ:LPTX) have been given an average broker rating score of 1.50 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and one has given a strong buy rating to the company.
Analysts have set a 1 year consensus price objective of $15.50 for the company and are expecting that the company will post ($0.78) earnings per share for the current quarter, according to Zacks. Zacks has also given Leap Therapeutics an industry rank of 188 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research lowered shares of Leap Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 12th.
An institutional investor recently bought a new position in Leap Therapeutics stock. Sabby Management LLC bought a new stake in shares of Leap Therapeutics Inc (NASDAQ:LPTX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned 0.72% of Leap Therapeutics at the end of the most recent quarter. Institutional investors own 1.33% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3225852/3225852.html.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.